1Department of Radiation Oncology, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea
2Department of Radiation Oncology, Chungnam National University School of Medicine, Daejeon, Korea
3Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul, Korea
4Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
5Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Korea
Copyright © 2017 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Study | Institution | Study period |
No. (%) |
Surgical treatment | T stage | N+ (%) | Adjuvant treatment | ||
---|---|---|---|---|---|---|---|---|---|
R0 mm | R0-1 mm | R>1 mm | |||||||
Campbell et al. (2009) [16] | Liverpool (UK) | 1997-2007 | 71 (43.6) | 57 (35.0) | 35 (21.5) | PPPD (90.2%), whipple (9.8%) | T3/4 (85.3%) | 78.5 | NA |
Chang et al. (2009) [23] | Sydney (Australia) | 1990-2007 | 132 (36.2) | 56 (15.3) | 177 (48.5) | Whipple (80.8%), left side pancreatectomy (19.2%) | > 2 cm (77.0%) | 59.5 | Adjuvant CTx (26.3%), RT (5.8%) |
Janot et al. (2012) [24] | Bochum (Germany) | 2007-2009 | 5 (8.1) | 12 (19.4) | 45 (72.6) | Whipple (11.3%), PPPD (69.3%), TP (19.4%) | T3/4 (91.9%), > 2.5 cm (66.1%) | 79.0 | NA |
Thomay et al. (2012) [25] | Philadelphia (USA) | 1991-2011 | 108 (36.4) | 54 (18.2) | 135 (45.5) | PD (100%) | NA | NA | Neoadjuvant CRT (34%) |
Jamieson et al. (2013) [17] | Glasgow (UK) | 1996-2011 | 111 (51.2) | 46 (21.2) | 60 (27.6) | PD (100%) | T3/4 (90.3%), > 3 cm (50.7%) | 80.2 | Adjuvant therapy (47.0%), neoadjuvant CTx (0.9%) |
Sugiura et al. (2013) [26] | Sizuoka (Japan) | 2002-2010 | 34 (16.3) | 40 (19.2) | 134 (64.4) | PD (78.8%), DP (20.2%), TP (1.0%) | > 3 cm (47.1%) | 69.2 | Adjuvant CTx (84.6%), RT (11.5%) |
Konstantinidis et al. (2013) [27] | MGH (USA) | 1993-2001 | 157 (31.7) | 169 (34.1) | 170 (34.3) | PD (83.1%), DP (15.3%), TP (1.4%) | T3/4 (88.5%) | 70.0 | NA |
Hashimoto et al. (2013) [28] | Wakayama (Japan) | 2002-2012 | 30 (24.2) | 38 (30.6) | 56 (45.2) | PD (100%) | NA | NA | NA |
R0 mm, involved margin; R0-1 mm, margin clearance with ≤ 1 mm; R>1 mm, margin with > 1 mm; PPPD, pylorus preserving pancreaticocduodenectomy; NA, not applicable; CTx, chemotherapy; RT, radiotherapy; TP, total pancreatectomy; PD, pancreaticoduodenectomy; CRT, chemoradiation; DP, distal pancreatectomy.
Study | Protocol | Evaluated margin |
---|---|---|
Campbell et al. (2009) [16] | RCP [20] | Pancreatic transection margin |
Medial (or superior mesenteric vessel) margin | ||
Posterior margin | ||
Proximal duodenal (or gastric) margin | ||
Distal duodenal margin | ||
Common bile duct margin | ||
Chang et al. (2009) [23] | Institutional | Pancreatic neck margin |
Portal vein/superior mesenteric vein margin | ||
Superior mesenteric artery/retroperitoneal (uncinate) margin | ||
Bile duct margin | ||
Proximal gastric/duodenal margin | ||
Distal duodenal margin | ||
Janot et al. (2012) [24] | Modified LEEPP [14] | Anterior margin |
Posterior margin (uncinate process) | ||
Superior mesenteric vein groove circumferential resection margin | ||
Transection margin (pancreatic neck, bile duct, and duodenum margin) | ||
Thomay et al. (2012) [25] | NA | NA |
Jamieson et al. (2013) [17] | RCP [20,31] | Posterior margin |
Anterior margin | ||
Medial margin | ||
Pancreatic transection margin | ||
Sugiura et al. (2013) [26] | Japan Pancreas Society [30] | Pancreatic transection margin |
Superior mesenteric artery margin | ||
Posterior margin | ||
Proximal bile duct margin | ||
Konstantinidis et al. (2013) [27] | Staley et al. [29] | Common bile duct margin |
Pancreatic transection (neck) margin | ||
Posterior/retroperitoneal margin | ||
Uncinate (superior mesenteric artery) margin | ||
Hashimoto et al. (2013) [28] | NA | NA |
Study |
Selection |
Performance |
Detection |
Attrition |
Reporting |
|
---|---|---|---|---|---|---|
Selection of participants | Confounding variables | Measurement of exposure | Blinding of outcome assessments | Incomplete outcome data | Selective outcome reporting | |
Campbell et al. (2009) [16] | Low | Low | Low | Low | Unclear | Low |
Chang et al. (2009) [23] | Low | Low | Low | Low | Low | Low |
Janot et al. (2012) [24] | Low | Low | Low | Low | Unclear | Low |
Thomay et al. (2012) [25] | Low | High | Low | Low | Unclear | Unclear |
Jamieson et al. (2013) [17] | Low | Low | Low | Low | Low | Low |
Sugiura et al. (2013) [26] | Low | Low | Low | Low | Unclear | Low |
Konstantinidis et al. (2013) [27] | Low | High | Low | Low | Unclear | Low |
Hashimoto et al. (2013) [28] | Low | High | Low | Low | Unclear | Unclear |
Study | Institution | Study period | No. (%) |
Surgical treatment | T stage | N+ (%) | Adjuvant treatment | ||
---|---|---|---|---|---|---|---|---|---|
R0 mm | R0-1 mm | R>1 mm | |||||||
Campbell et al. (2009) [16] | Liverpool (UK) | 1997-2007 | 71 (43.6) | 57 (35.0) | 35 (21.5) | PPPD (90.2%), whipple (9.8%) | T3/4 (85.3%) | 78.5 | NA |
Chang et al. (2009) [23] | Sydney (Australia) | 1990-2007 | 132 (36.2) | 56 (15.3) | 177 (48.5) | Whipple (80.8%), left side pancreatectomy (19.2%) | > 2 cm (77.0%) | 59.5 | Adjuvant CTx (26.3%), RT (5.8%) |
Janot et al. (2012) [24] | Bochum (Germany) | 2007-2009 | 5 (8.1) | 12 (19.4) | 45 (72.6) | Whipple (11.3%), PPPD (69.3%), TP (19.4%) | T3/4 (91.9%), > 2.5 cm (66.1%) | 79.0 | NA |
Thomay et al. (2012) [25] | Philadelphia (USA) | 1991-2011 | 108 (36.4) | 54 (18.2) | 135 (45.5) | PD (100%) | NA | NA | Neoadjuvant CRT (34%) |
Jamieson et al. (2013) [17] | Glasgow (UK) | 1996-2011 | 111 (51.2) | 46 (21.2) | 60 (27.6) | PD (100%) | T3/4 (90.3%), > 3 cm (50.7%) | 80.2 | Adjuvant therapy (47.0%), neoadjuvant CTx (0.9%) |
Sugiura et al. (2013) [26] | Sizuoka (Japan) | 2002-2010 | 34 (16.3) | 40 (19.2) | 134 (64.4) | PD (78.8%), DP (20.2%), TP (1.0%) | > 3 cm (47.1%) | 69.2 | Adjuvant CTx (84.6%), RT (11.5%) |
Konstantinidis et al. (2013) [27] | MGH (USA) | 1993-2001 | 157 (31.7) | 169 (34.1) | 170 (34.3) | PD (83.1%), DP (15.3%), TP (1.4%) | T3/4 (88.5%) | 70.0 | NA |
Hashimoto et al. (2013) [28] | Wakayama (Japan) | 2002-2012 | 30 (24.2) | 38 (30.6) | 56 (45.2) | PD (100%) | NA | NA | NA |
Study | Protocol | Evaluated margin |
---|---|---|
Campbell et al. (2009) [16] | RCP [20] | Pancreatic transection margin |
Medial (or superior mesenteric vessel) margin | ||
Posterior margin | ||
Proximal duodenal (or gastric) margin | ||
Distal duodenal margin | ||
Common bile duct margin | ||
Chang et al. (2009) [23] | Institutional | Pancreatic neck margin |
Portal vein/superior mesenteric vein margin | ||
Superior mesenteric artery/retroperitoneal (uncinate) margin | ||
Bile duct margin | ||
Proximal gastric/duodenal margin | ||
Distal duodenal margin | ||
Janot et al. (2012) [24] | Modified LEEPP [14] | Anterior margin |
Posterior margin (uncinate process) | ||
Superior mesenteric vein groove circumferential resection margin | ||
Transection margin (pancreatic neck, bile duct, and duodenum margin) | ||
Thomay et al. (2012) [25] | NA | NA |
Jamieson et al. (2013) [17] | RCP [20,31] | Posterior margin |
Anterior margin | ||
Medial margin | ||
Pancreatic transection margin | ||
Sugiura et al. (2013) [26] | Japan Pancreas Society [30] | Pancreatic transection margin |
Superior mesenteric artery margin | ||
Posterior margin | ||
Proximal bile duct margin | ||
Konstantinidis et al. (2013) [27] | Staley et al. [29] | Common bile duct margin |
Pancreatic transection (neck) margin | ||
Posterior/retroperitoneal margin | ||
Uncinate (superior mesenteric artery) margin | ||
Hashimoto et al. (2013) [28] | NA | NA |
Study | Selection |
Performance |
Detection |
Attrition |
Reporting |
|
---|---|---|---|---|---|---|
Selection of participants | Confounding variables | Measurement of exposure | Blinding of outcome assessments | Incomplete outcome data | Selective outcome reporting | |
Campbell et al. (2009) [16] | Low | Low | Low | Low | Unclear | Low |
Chang et al. (2009) [23] | Low | Low | Low | Low | Low | Low |
Janot et al. (2012) [24] | Low | Low | Low | Low | Unclear | Low |
Thomay et al. (2012) [25] | Low | High | Low | Low | Unclear | Unclear |
Jamieson et al. (2013) [17] | Low | Low | Low | Low | Low | Low |
Sugiura et al. (2013) [26] | Low | Low | Low | Low | Unclear | Low |
Konstantinidis et al. (2013) [27] | Low | High | Low | Low | Unclear | Low |
Hashimoto et al. (2013) [28] | Low | High | Low | Low | Unclear | Unclear |
R0 mm, involved margin; R0-1 mm, margin clearance with ≤ 1 mm; R>1 mm, margin with > 1 mm; PPPD, pylorus preserving pancreaticocduodenectomy; NA, not applicable; CTx, chemotherapy; RT, radiotherapy; TP, total pancreatectomy; PD, pancreaticoduodenectomy; CRT, chemoradiation; DP, distal pancreatectomy.
RCP, Royal College of Pathologist; LEEPP, Leeds Pathology Protocol; NA, not applicable.